Australia is among few countries in the world making notable progress in the field of medicinal cannabis, which is believed to have traits that can cure cancer, epilepsy, seizures, AIDS and other critical ailments. Legalisation of medicinal cannabis (at federal level) in Australia in February 2016 has resulted in a tide of investments, employment opportunities and booming businesses, in addition to enhancing the country’s relations with global markets. By the end of 2025, cannabis market in Australia is anticipated to have ~AUD 55 million in net worth.
The traction in the flourishing Australian cannabis market is attracting several players. One such player is Greenfield MC, an innovative medicinal cannabis start-up, which seems to be taking the cannabis baton in its hands. Let us have a broader look at the company.
About Greenfield MC
Headquartered in Sydney, Australia, Greenfield MC operates as a licensed medicinal cannabis importer and distributor, dealing in medicinal cannabis products, including balms, oils, soft gel capsules and tinctures. With a vision of becoming the top player in the field of medicinal cannabis wholesale and patient-retailing in Asia-Pacific, the company is boosting its operations in the areas of cultivation, research and distribution in countries including New Zealand and South Korea. Its global team is based out of Sydney, Melbourne and Brisbane in Australia, Auckland in New Zealand, Seoul in South Korea and Manila in the Philippines.
As part of its goal of ensuring life-changing medicine access to patients at the lowest cost and highest quality, the independent privately-owned company works in collaboration with hospitals, manufacturers, and medical professionals, including doctors, pharmacists and compounders. Moreover, in order to attain vertical integration with low-cost cultivation and distribution networks in various markets, Greenfield MC has formed joint ventures with international players. The company distributes its products to more than 200 hospitals and 3,500 phamacies.
Investment Round Plans in Late Q319
To further support its vision, the company is planning to raise AUD 2-2.5 million in a Series B investment round by the end of third quarter of the year 2019. This is expected to be an inspiring and lucrative next chapter for Greenfield MC, which is focused on medicine, science, and results. The funding round would be supported by its executive team, operations in the Asia-Pacific region, cutting-edge plans related to cultivation and research and its JV with a publicly listed Canadian commercial cannabis producer.
Leading Oncologist on Medical Board
As an innovative medicinal cannabis start-up in Australia, Greenfield MC seems to be leaving no stone unturned to achieve its vision of becoming the leading medicinal cannabis supplier and producer in Asia-Pacific region. The company is bringing onboard high-profile leaders from the medical and pharmaceutical industries.
Bringing in several years of experience in the field of clinical oncology, Dr Sree is expected to make significant contributions towards the company’s vision. Not only an academic researcher, Dr Sree has published over 50 articles in multiple medical journals that were peer reviewed.
Industry Leaders on Medical Board
Dr Ben Barresi
Having the best people to deliver the best product is what Greenfield MC believes in. Dr Ben Barresi is a high-profile sports doctor, who is another key member on the company’s medical board. An MBBS with the Fellowship of the Royal Australian College of General Practitioners (FRACGP), Dr Ben is a General Practitioner holding specialisation in the fields of sports medicine as well as addiction medicine. Currently, he is serving as the match day doctor for the Greater Western Sydney Giants for their Victorian fixtures. Besides, he is a medical advisor to Comcare and WorkSafe Victoria. Additionally, Dr Ben is engaged in delivering GP liaison support for admitting treating psychiatrists who are involved in inpatient management at programs related to substance disorders at The Melbourne Clinic.
His prior association has been with the Australian Football League as a team physician. Dr Ben has also made contributions in important research studies by the AFL related to shoulder instability, concussion and hamstring injuries.
Prof. Robert Iansek
A neurologist, Prof. Robert is also serving as the Director of the Victorian Comprehensive Parkinson’s Program at Kingston Centre, Southern Health and of Clinical Research Centre for Movement Disorders & Gait. A feather in Prof. Robert’s cap is his “Order of Australia” award for contributions towards medicine in the field of neurology. He has also made significant contributions in peer-reviewed journals and multiple other publications.
Associate Prof. Ajeet Singh
Strengthening the company’s member board with his expertise as a Psychiatrist and Pharmacogeneticist, Associate Prof. Ajeet is the founder of genetic testing company CNSDose. He holds vast work experience from his previous appointments in several medical facilities including Thomas Embling Forensic Psychiatry Hospital, The Alfred Hospital, and Geelong Hospital and Clinic.
Dr Dharshi Karalapillai
He is an anaesthetist and ICU expert. Holding a degree in MBBS, FCICM, FANZCA and DDU, Dr Dharshi Karalapillai has worked with several medical facilities including Royal Melbourne Hospital, Austin Hospital, and Peter Macallum Hospital. Moreover, he has written a number of research writeups in peer-reviewed publications.
Mr Nicholas Hanna is the Chief Executive Officer of Greenfield MC, who is heading the company’s highly regarded and well-respected health professionals’ team. He is a lawyer and holds significant experience in the medicinal cannabis space in Australia. Mr Nicholas also has significant interests in medicinal cannabis assets in countries including the United States, Canada, Colombia and Germany. Mr Arjun Chhabra is the Chairman and President of the company. A lawyer by education, Mr Arjun boasts vast experience in working with start-ups and in emerging markets. His previous employments have been with renowned companies like Deloitte and Baker McKenzie.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.